miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 24, 2026

Jensen Huang Sees $1 Trillion in Demand: 3 AI Stocks to Buy Now

View original at nasdaq.com
“the company converted that revenue into $120 billion in profit”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analysts expect Nvidia earnings to grow at 22 times this year's earnings and 17 times next year's consensus earnings estimate

    60% confidence

  • Stock Advisor's total average return is 898%, compared to 183% for the S&P 500

    60% confidence

  • Stock Advisor's total average return is 898% compared to 183% for the S&P 500

    60% confidence

  • Nvidia is one of the top AI stock holdings for hedge funds

    60% confidence

  • Demand was $500 billion worth a year ago

    60% confidence

  • OpenAI's partnership with AWS could drive 'enormous consumption' of cloud computing

    60% confidence

  • OpenAI's partnership with AWS could drive enormous consumption of cloud computing

    60% confidence

  • The 10 best stocks for investors to buy now do not include Nvidia

    60% confidence

  • OpenAI's recent partnership with AWS could drive enormous consumption of cloud computing

    60% confidence

  • OpenAI's recent partnership with AWS could drive enormous consumption of cloud computing

    60% confidence

  • There is roughly $1 trillion of cumulative demand for Nvidia's Blackwell and Rubin chips through 2027

    60% confidence

  • Analysts expect Dell earnings to grow at an annualized rate of 15% in the next several years

    60% confidence

  • CUDA is the key piece of Nvidia's moat

    60% confidence

  • Nvidia remains one of the top AI stock holdings for hedge funds

    60% confidence

  • There was $500 billion worth of demand for Nvidia chips a year ago

    60% confidence

  • There is roughly $1 trillion of cumulative demand for Nvidia's Blackwell and Rubin chips through 2027

    60% confidence

  • Nvidia remains one of the top AI stock holdings for hedge funds

    60% confidence

  • There is roughly $1 trillion of cumulative demand for Nvidia's Blackwell and Rubin chips through 2027

    60% confidence

  • Analysts expect Amazon earnings to grow 18% annually in the coming years

    60% confidence

  • Demand for AI services exceeded AWS data center capacity during 2025

    60% confidence

  • There is roughly $1 trillion of cumulative demand for Nvidia's Blackwell and Rubin chips through 2027

    60% confidence

  • AI demand remains strong

    60% confidence

  • Previous year's demand estimate was $500 billion

    60% confidence

  • AWS left some revenue on the table during 2025, as demand for AI services exceeded the capacity of its data centers

    60% confidence

  • Previous year's demand forecast was $500 billion worth of demand

    60% confidence

Data points we hold from this source

Amazon Web Services · profit contribution50 percent
Dell Technologies · pe ratio forward12 ratio
Dell Technologies · earnings growth forecast15 percent
Dell Technologies · forward pe ratio12 ratio
Dell Technologies · expected earnings growth15 percent_annual
Dell Technologies · ai server revenue9 USD
Dell Technologies · infrastructure revenue61 USD
Dell Technologies · infrastructure revenue61 USD
Dell Technologies · ai server revenue9 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Jensen Huang Sees $1 Trillion in Demand: 3 AI Stocks to Buy Now — Source | Via News | es.VIA.NEWS